Details of the Drug Reposition

General Information of This Drug (ID: DMHT34O)

Drug Name
Gemifloxacin   DMHT34O
Synonyms
Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Streptococcal pneumonia DIS2EKMJ N.A. Approved [1]
Mycoplasma pneumoniae pneumonia DIS1AW2Z N.A. Approved [1]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial pneumonia DISPW7PH CA40.0 Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pneumonia caused by chlamydia DISX7CHR N.A. Investigative [1]
------------------------------------------------------------------------------------

References

1 Gemifloxacin FDA Label
2 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
3 CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia